CL2007001961A1 - Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. - Google Patents

Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.

Info

Publication number
CL2007001961A1
CL2007001961A1 CL2007001961A CL2007001961A CL2007001961A1 CL 2007001961 A1 CL2007001961 A1 CL 2007001961A1 CL 2007001961 A CL2007001961 A CL 2007001961A CL 2007001961 A CL2007001961 A CL 2007001961A CL 2007001961 A1 CL2007001961 A1 CL 2007001961A1
Authority
CL
Chile
Prior art keywords
dienogest
tetrahydrofolate
methyl
contraception
risk
Prior art date
Application number
CL2007001961A
Other languages
English (en)
Inventor
Claus Claussen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06016950A external-priority patent/EP1891959A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2007001961A1 publication Critical patent/CL2007001961A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composición farmacéutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato o b) 1,5 mg de dienogest y 0,015 mg de etinilestradiol y(6s)-5-metil-tetrahidrofolato; kit que la contiene; y uso para la anticoncepción y para reducir el riesgo de malformación congénita.
CL2007001961A 2006-07-06 2007-07-05 Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. CL2007001961A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06
EP06016950A EP1891959A1 (de) 2006-08-14 2006-08-14 Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen

Publications (1)

Publication Number Publication Date
CL2007001961A1 true CL2007001961A1 (es) 2008-01-11

Family

ID=38330771

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001961A CL2007001961A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.

Country Status (16)

Country Link
US (1) US20080268048A1 (es)
EP (1) EP2037935A1 (es)
JP (1) JP2009542588A (es)
KR (1) KR20090029824A (es)
AR (1) AR061959A1 (es)
BR (1) BRPI0713999A2 (es)
CA (1) CA2665788A1 (es)
CL (1) CL2007001961A1 (es)
DE (1) DE112007001600A5 (es)
IL (1) IL196154A0 (es)
MX (1) MX2009000256A (es)
PE (1) PE20080400A1 (es)
RU (1) RU2009102443A (es)
TW (1) TW200810764A (es)
UY (1) UY30461A1 (es)
WO (1) WO2008003363A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
EP3781171B1 (en) 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CA2329005C (en) * 1998-04-17 2006-01-03 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US7696219B2 (en) * 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
JP5037779B2 (ja) * 2002-02-21 2012-10-03 バイエル ファーマ アクチエンゲゼルシャフト １又は複数のステロイド、１又は複数のテトラヒドロ葉酸成分およびビタミンｂ１２を含む医薬組成物
WO2005115349A1 (de) * 2004-05-28 2005-12-08 Grünenthal GmbH Folsäurehaltiges kontrazeptivum
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
BRPI0713999A2 (pt) 2012-11-20
AR061959A1 (es) 2008-08-10
TW200810764A (en) 2008-03-01
KR20090029824A (ko) 2009-03-23
DE112007001600A5 (de) 2009-04-30
PE20080400A1 (es) 2008-07-04
EP2037935A1 (de) 2009-03-25
WO2008003363A1 (de) 2008-01-10
UY30461A1 (es) 2008-02-29
CA2665788A1 (en) 2008-01-10
RU2009102443A (ru) 2010-08-20
MX2009000256A (es) 2009-02-18
US20080268048A1 (en) 2008-10-30
JP2009542588A (ja) 2009-12-03
IL196154A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
AR061958A1 (es) Composicion farmaceutica que contiene un acido tetrahidrofolico
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
ES2525320T3 (es) Composiciones de calentamiento y sistemas para su descarga
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
ECSP066999A (es) Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
WO2006128907A3 (en) Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
DE602005020694D1 (de) Pharmazeutische zusammensetzung mit drospirenon und ethinylöstradiol
PL1933843T3 (pl) Wykorzystanie walerianianu estradiolu lub estradiolu w kombinacji z dienogestem do doustnej terapii czynnościowego krwawienia macicznego w formie doustnej antykoncepcji
HRP20080394T3 (hr) Peroralna dozna forma u krutom stanju namjenjena kontracepciji, koja sadrži dienogest i etinilestradiol
CL2008001147A1 (es) Combinacion farmaceutica que comprende 11b-(4-acetilfenil)-17b-hidroxi-17 (1,1,2,2,2-pentafluoroetil) estra-4,9-dien-3-ona junto con al menos un antiestrogeno no esteroidal puro; y uso para la profilaxis o el tratamientodel cancer mediado por brca1 o brca2.
PE20080541A1 (es) Forma farmacologica peroral para la anticoncepcion
BRPI0815756A2 (pt) Uso de gestagênios em combinação com (6s)5-metiltetra-hidrofolato para a terapia da endometriose com redução simultânea de efeitos colaterais da terapia bem como a redução do risco de malformações congênitas no caso de gravidez.
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
NZ737002A (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
PE20061291A1 (es) Composicion farmaceutica que contiene dienogest y etinilestradiol
CU20070252A7 (es) Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico
PE20091695A1 (es) COMBINACION FARMACEUTICA DE DROSPIRENONA Y 17ß-ESTRADIOL
TH0601005011A (th) การใช้เอสตราไดออลวาเลอเรตหรือเอสตราไดออลร่วมกับไดอีโนเจสต์สำหรับการรักษาโดยให้ทางปากในการตกเลือดในมดลูกแบบที่ทำงานผิดปกติ ร่วมกับยาคุมกำเนิดสำหรับให้ทางปาก
BRMU8700723U (pt) aperfeiçoamentos introduzidos em pistão e válvula para pneumáticos
BRPI0819189A2 (pt) Uso de um gestagênio em combinação com estrogênio e um ou mais excipientes/veículos farmaceuticamente aceitáveis para a contracepção oral livre de lactose.